A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.

Tol, J

A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology Apr 2008 - 734-8 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1569-8041

10.1093/annonc/mdm607 doi


Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Bevacizumab
Capecitabine
Carcinoma--drug therapy
Cetuximab
Colorectal Neoplasms--drug therapy
Deoxycytidine--administration & dosage
Disease-Free Survival
Drug Eruptions--etiology
Female
Fluorouracil--administration & dosage
Humans
Incidence
Male
Middle Aged
Netherlands
Organoplatinum Compounds--administration & dosage
Oxaliplatin
Severity of Illness Index
Survival Analysis
Treatment Outcome